Fti Consulting (FCN) Stock Price, Quote & News

Company Profile

FTI Consulting, Inc. provides business advisory services to manage change, mitigate risk, and resolve disputes worldwide. The company operates through Corporate Finance & Restructuring; Forensic and Litigation Consulting; Economic Consulting; and Technology, and Strategic Communications segments. The Corporate Finance & Restructuring segment provides business transformation and strategy, transactions, and turnaround and restructuring services. The Forensic and Litigation Consulting segment offer...

Industry: Consulting Services

Sector: Industrials

Phone: 202 312 9100

Fax: 202 312 9101

Website: www.fticonsulting.com

Address:

555 12th Street NW, Suite 700, Washington, United States

lmdxxxxxxxxxx Jan. 5 at 1:08 PM

$FCN $LMDX $RHHBY These statements were presented as forward-looking, yet shareholders were ultimately told they would receive nothing, while the same intellectual property and R&D continue generating value elsewhere with substantially the same personnel involved. Formal investigation. https://www.sec.gov/submit-tip-or-complaint

0 · Reply

lmdxxxxxxxxxx Jan. 5 at 12:49 PM

$FCN $LMDX $RHHBY $SPY https://www.sec.gov/submit-tip-or-complaint If they still have your best interest in mind this is just insurance, Do what it right. Don’t follow the divergence.

0 · Reply

ImYourPhuckleberry Jan. 4 at 7:01 PM

$FCN $LMDX $RHHBY $SPY It's literally our device, utilizing our strips. Ron and Veronique, you must be crazy to think you'll get away with this.

0 · Reply

lmdxxxxxxxxxx Jan. 4 at 6:37 PM

$FCN $LMDX $RHHBY $SPY Thank you for these Facts.

0 · Reply

lmdxxxxxxxxxx Jan. 4 at 6:32 PM

$LMDX $FCN $RHHBY DW and the divergence attempts baffle me … the facts are out there. Truth is catching up and you can’t hide from it. Here are the forward looking statements I read. https://www.sec.gov/submit-tip-or-complaint/tips-complaints-resources/report-suspected-securities-fraud-or-wrongdoing

0 · Reply

Dww0311 Jan. 4 at 5:37 PM

$LMDX $RHHBY $FCN $SPY Not "you should have known" "You were told and failed to understand" Those are not remotely the same thing.

0 · Reply

lmdxxxxxxxxxx Jan. 4 at 5:34 PM

$FCN $LMDX $RHHBY $SPY

0 · Reply

lmdxxxxxxxxxx Jan. 4 at 5:31 PM

$FCN $LMDX $RHHBY $SPY “You should have known it would fail” is not a securities-law defense. Disclosure is judged by what was known and withheld at the time—not by the outcome. ✌️ Don’t forget shareholders… https://www.sec.gov/submit-tip-or-complaint/tips-complaints-resources/report-suspected-securities-fraud-or-wrongdoing

1 · Reply

Dww0311 Jan. 4 at 5:22 PM

$LMDX $RHHBY $FCN $SPY Yet again ... "I believe this happened" is a great deal of distance away from "I have hard evidence that this happened". I'll humor you though ... What was materially misstated or omitted? Their filings made it clear, over the course of more than two years, that they were mortgaged right down to the doorknobs and were going to collapse into bankruptcy. If you weren't aware of that, then you didn't read them. What was fraudulently conveyed? Biopharma held a blanket lien on ALL of their assets, which it exercised when they defaulted. We call that foreclosure, not fraudulent conveyance. What conflicted transactions? What improper asset transfers? What misleading disclosures? (See item 1, above ...) The shareholders were told, point blank, that this company was on borrowed time and would - without any doubt - collapse. I get that you feel umbrage at being fk'ed, like every shareholder in every bankruptcy in history, but speaking frankly here - you guys fk'ed yourselves.

0 · Reply

lmdxxxxxxxxxx Jan. 4 at 5:13 PM

$FCN $LMDX $RHHBY $SPY Courts routinely recognize standing for shareholders alleging: • material misstatements or omissions, • fraudulent conveyance, • conflicted transactions, • improper asset transfers, • or misleading disclosures that induced investment or continued holding. The issue is not whether LumiraDx ultimately failed. The issue is whether shareholders were told the truth, whether assets were properly accounted for, and whether insiders acted lawfully during distress. Those questions remain open and are precisely why further regulatory and legal scrutiny is appropriate. You have your opinion. I have my facts lined up. ✌️

0 · Reply

FTI Consulting Adds Forensic Accounting and Investigations Expert Mavis Tan in Asia

Dec 17, 2025, 7:30 AM EST - 20 days ago

Renowned AI Expert Xi Chen Joins Compass Lexecon

Dec 17, 2025, 7:11 AM EST - 20 days ago

Penguin Ai and FTI Unite Expertise to Deliver Next-Generation Revenue Cycle Performance

Dec 16, 2025, 7:30 AM EST - 21 days ago

FTI Consulting Survey Shows Life Sciences Leaders' Outlook Tempered by Concerns Around Fundraising, Policy Shifts and Cybersecurity Heading into 2026

Dec 10, 2025, 7:30 AM EST - 27 days ago

FTI Consulting Expands Healthcare Risk Management & Advisory Practice with Appointment of Mitch Harris as Senior Managing Director

Dec 9, 2025, 8:30 AM EST - 4 weeks ago

FTI Consulting Appoints Rike Rabl as Chief Human Resources Officer

Dec 3, 2025, 7:00 PM EST - 4 weeks ago

FTI Consulting Appoints Jason Leow to Strategic Communications Segment in Singapore

Dec 3, 2025, 3:30 AM EST - 5 weeks ago

FTI Consulting Continues Private Equity and Financial Services Investment With Addition of Four Senior Hires

Nov 10, 2025, 3:00 AM EST - 2 months ago

FTI Consulting Continues Investment in EMEA Tax Capabilities with Addition of Two Senior Hires

Oct 23, 2025, 12:47 PM EDT - 2 months ago

FTI Consulting, Inc. (FCN) Q3 2025 Earnings Call Transcript

Oct 23, 2025, 7:30 AM EDT - 2 months ago

FTI Consulting Reports Record Third Quarter 2025 Financial Results

Oct 21, 2025, 5:00 PM EDT - 2 months ago

FTI Consulting Enhances Risk & Investigations Capabilities in Australia with Appointment of Warren Dunn as a Senior Managing Director

Oct 16, 2025, 8:30 AM EDT - 2 months ago

FTI Consulting Continues Global Investments in Financial Services Sector

Oct 15, 2025, 7:30 AM EDT - 2 months ago

FTI Consulting Adds Former FBI Deputy Director Paul Abbate to National Security Team

Oct 13, 2025, 7:30 AM EDT - 3 months ago

Compass Lexecon Adds Antitrust and Finance Expertise with Two Senior Hires

Oct 2, 2025, 7:30 AM EDT - 3 months ago

FTI Consulting to Release Third Quarter 2025 Results and Host Conference Call

Sep 29, 2025, 7:30 AM EDT - 3 months ago

FTI Consulting Adds Regulatory Compliance Expert James Needham to Export Controls, Sanctions & Trade Practice

Sep 16, 2025, 2:00 AM EDT - 4 months ago

FTI Consulting Strengthens Capabilities in Germany with Addition of Senior Cybersecurity Expert

Sep 10, 2025, 7:30 AM EDT - 4 months ago

FTI Consulting Bolsters Threat Intelligence Capabilities with Appointment of Keith Wojcieszek

Sep 9, 2025, 7:30 AM EDT - 4 months ago

Compass Lexecon Adds Three Leading Economic and Antitrust Experts

Sep 8, 2025, 7:30 AM EDT - 4 months ago

FTI Consulting Appoints Shaun Rangappa, MD, MSHA, as Chief Clinical Executive and Senior Managing Director in Healthcare Business Transformation Practice

Sep 1, 2025, 9:00 PM EDT - 4 months ago

FTI Consulting Expands Corporate Finance & Restructuring Segment in Asia with Appointment of Hitesh Tak as Senior Managing Director

Aug 31, 2025, 6:00 PM EDT - 4 months ago

FTI Consulting Strengthens Australia Public Sector Leadership with Appointment of Steven Casey

Aug 13, 2025, 8:30 AM EDT - 5 months ago

Compass Lexecon Ranked Top Economic Consulting Firm on Lexology Index Competition 2025 List

Aug 12, 2025, 7:00 AM EDT - 5 months ago

FTI Consulting Announces CFO Transition

Aug 4, 2025, 8:00 PM EDT - 5 months ago

FTI Consulting Expands Forensic and Litigation Consulting Segment in Asia with Appointment of Martin Tupila as Senior Managing Director

Jul 30, 2025, 6:00 PM EDT - 5 months ago

FTI Consulting Names Pat McLay as Leader of Accounting Advisory Practice in Australia

Jul 28, 2025, 6:00 PM EDT - 5 months ago

Digital Transformation Expert Sabine Bennett Joins FTI Consulting's Healthcare & Human Services Practice in Australia

Jul 28, 2025, 7:30 AM EDT - 5 months ago

Health Insurance and Policy Expert Elizabeth Goodman Joins FTI Consulting's Healthcare and Life Sciences Practice

Jul 24, 2025, 2:22 PM EDT - 5 months ago

FTI Consulting, Inc. (FCN) Q2 2025 Earnings Call Transcript

Jul 24, 2025, 7:30 AM EDT - 5 months ago

FTI Consulting Reports Second Quarter 2025 Financial Results

Jul 9, 2025, 7:30 AM EDT - 6 months ago

FTI Consulting Expands Export Controls, Sanctions and Trade Practice with Appointment of Two Industry Leaders

Jul 7, 2025, 6:00 PM EDT - 6 months ago

FTI Consulting Expands Cybersecurity Capabilities in Australia with Appointment of Natasha Passley

Jul 7, 2025, 7:30 AM EDT - 6 months ago

FTI Consulting Report: An Endgame for the Epic E-Commerce Era Is Within Sight

Jul 2, 2025, 7:30 AM EDT - 6 months ago

FTI Consulting to Release Second Quarter 2025 Results and Host Conference Call

Jul 1, 2025, 3:00 AM EDT - 6 months ago

FTI Consulting Appoints Joseph Shipley to Lead Private Equity Offering within the Strategic Communications Segment in London and across EMEA

Jun 30, 2025, 7:30 AM EDT - 6 months ago

Banking and Payments Expert Joins FTI Consulting as Senior Managing Director

Jun 24, 2025, 4:30 AM EDT - 7 months ago

FTI Consulting Survey: Majority of Private Equity Leaders Say M&A Is Not a Top Priority for 2025

Jun 4, 2025, 7:30 AM EDT - 7 months ago

FTI Consulting's Construction, Projects & Assets Practice Adds Digital Transformation Expert Mark White

Jun 2, 2025, 6:00 PM EDT - 7 months ago

FTI Consulting Adds Risk & Compliance Expert Mark Gossington in Australia

May 20, 2025, 7:30 AM EDT - 8 months ago

FTI Consulting Announces Technology Alliance with BigID

May 19, 2025, 7:30 AM EDT - 8 months ago

Renowned IO Economist Professor B. Douglas Bernheim Affiliates with Compass Lexecon

May 15, 2025, 7:30 AM EDT - 8 months ago

New FTI Consulting Survey Reveals Mounting Challenges Continue for U.S. Hospitals

May 14, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against FTI Consulting, Inc. (FCN) And Encourages Shareholders to Reach Out

May 13, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against FTI Consulting, Inc. (FCN) and Encourages Shareholders to Learn More About the Investigation

May 12, 2025, 10:00 AM EDT - 8 months ago

FTI Consulting, Inc. (FCN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

May 12, 2025, 3:00 AM EDT - 8 months ago

Financial Services Expert Julien Wallen Joins FTI Consulting as Senior Managing Director

May 11, 2025, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages FTI Consulting, Inc. (FCN) Shareholders to Inquire about Securities Investigation

lmdxxxxxxxxxx Jan. 5 at 1:08 PM

0 · Reply

lmdxxxxxxxxxx Jan. 5 at 12:49 PM

$FCN $LMDX $RHHBY $SPY https://www.sec.gov/submit-tip-or-complaint If they still have your best interest in mind this is just insurance, Do what it right. Don’t follow the divergence.

0 · Reply

ImYourPhuckleberry Jan. 4 at 7:01 PM

$FCN $LMDX $RHHBY $SPY It's literally our device, utilizing our strips. Ron and Veronique, you must be crazy to think you'll get away with this.

0 · Reply

lmdxxxxxxxxxx Jan. 4 at 6:37 PM

$FCN $LMDX $RHHBY $SPY Thank you for these Facts.

0 · Reply

lmdxxxxxxxxxx Jan. 4 at 6:32 PM

0 · Reply

Dww0311 Jan. 4 at 5:37 PM

$LMDX $RHHBY $FCN $SPY Not "you should have known" "You were told and failed to understand" Those are not remotely the same thing.

0 · Reply

lmdxxxxxxxxxx Jan. 4 at 5:34 PM

$FCN $LMDX $RHHBY $SPY

0 · Reply

lmdxxxxxxxxxx Jan. 4 at 5:31 PM

1 · Reply

Dww0311 Jan. 4 at 5:22 PM

0 · Reply

lmdxxxxxxxxxx Jan. 4 at 5:13 PM

0 · Reply

Dww0311 Jan. 4 at 2:50 PM

$LMDX $RHHBY $FCN $SPY Lumira was not restructured. It was liquidated and dissolved. You need to understand that Biopharma seized all of Lumira’s assets - including all of its IP - when Lumira defaulted. From that second forward, the company you held shares in was an empty shell devoid of assets. Roche technically bought what it bought from Biopharma, not Lumira. At that point Lumira had nothing to sell. Helpful example - you might have made hundreds of mortgage payments prior to the bank foreclosing on your house, but once it does they don’t matter. You still don’t own the house any longer. The bank does. That’s what happened here. There just isn’t a basis for bringing suit, to be frank. You have no economic interest that substantiates standing.

0 · Reply

lmdxxxxxxxxxx Jan. 4 at 8:19 AM

$FCN $LMDX $RHHBY $SPY $LMDX Here is a comparative table and independent third-party materials that may be relevant to ongoing discussions about LumiraDx’s platform value and post-restructuring outcomes. Like they said our only chance is to let the sec know. The company is dissolved;!but the ip we invested in lives on without us. https://www.sec.gov/submit-tip-or-complaint/tips-complaints-resources/report-suspected-securities-fraud-or-wrongdoing

0 · Reply

ImYourPhuckleberry Jan. 3 at 4:48 PM

$LMDX $RHHBY $FCN He's doing the Lord's work, and half of our would-be attorneys' work as well. Slam dunk.

2 · Reply

lmdxxxxxxxxxx Jan. 3 at 5:03 AM

$FCN $LMDX $RHHBY 👁️👁️ $SPY 🐂 💩 🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨🚨 Leadership continuity is explicitly stated: ElectraDx’s CEO is Veronique Ameye, with founder and chair Ron Zwanziger—the same individuals central to LumiraDx’s restructuring and subsequent collapse. This regulator-filed document confirms that a commercially viable diagnostics platform attracted institutional capital and exclusive national market rights shortly after LumiraDx’s wind-down. Yet LumiraDx public shareholders received no recovery and no explanation as to how this value survived elsewhere.

0 · Reply

lmdxxxxxxxxxx Jan. 3 at 5:02 AM

$FCN $LMDX $RHHBY 🚨🚨🚨🚨 👁️👁️ $SPY some 🐂 💩 On November 14, 2025, Tauns Corporation filed an official exchange disclosure confirming a capital and business alliance with ElectraDx, Inc.. The filing establishes that Tauns invested in ElectraDx through Series B preferred shares and received exclusive sales and distribution rights in Japan, alongside agreements covering joint R&D, manufacturing, and commercialization. The disclosure describes ElectraDx as possessing a lab-grade, multi-analyte POCT and at-home diagnostics platform, integrating electrochemical sensing, intelligent test strips, and cloud connectivity for chronic and acute disease testing. These are the same platform-level technologies previously promoted as LumiraDx’s core assets.

0 · Reply

lmdxxxxxxxxxx Jan. 3 at 5:00 AM

$LMDX $RHHBY $FCN 🚨🚨🚨👁️👁️ Anyone care to comment on this?

0 · Reply

lmdxxxxxxxxxx Jan. 3 at 4:53 AM

🚨🚨🚨$LMDX $RHHBY $FCN 🚨🚨🚨 Anyone Want to Take a Go at This? 👁️👁️ $SPY on you On November 14, 2025, Tauns Corporation filed an official exchange disclosure confirming a capital and business alliance with ElectraDx, Inc.. The filing establishes that Tauns invested in ElectraDx through Series B preferred shares and received exclusive sales and distribution rights in Japan, alongside agreements covering joint R&D, manufacturing, and commercialization. The disclosure describes ElectraDx as possessing a lab-grade, multi-analyte POCT and at-home diagnostics platform, integrating electrochemical sensing, intelligent test strips, and cloud connectivity for chronic and acute disease testing. These are the same platform-level technologies previously promoted as LumiraDx’s core assets. Leadership continuity is explicitly stated: ElectraDx’s CEO is Veronique Ameye, with founder and chair Ron Zwanziger—the same individuals central to LumiraDx’s restructuring and subsequent collapse.

0 · Reply

lmdxxxxxxxxxx Jan. 3 at 4:46 AM

🚨🚨🚨$LMDX $RHHBY $FCN 🚨🚨🚨 $SPY This needs to be investigated. Take care of the shareholders that invested in this technology. 👁️👁️

0 · Reply

lmdxxxxxxxxxx Jan. 3 at 4:34 AM

🚨🚨🚨$LMDX $RHHBY $FCN 🚨🚨🚨 👁️👁️ What do we have here….. please do tell.

0 · Reply

lmdxxxxxxxxxx Jan. 1 at 3:34 AM

$LMDX $FCN $RHHBY 2026 Time to make it Happen! Cheers!

0 · Reply

lmdxxxxxxxxxx Dec. 31 at 2:57 AM

$LMDX $RHHBY $FCN $SPY The UK CMA confirmed LumiraDx had a viable future — and its IP went far beyond POC tests. A global diagnostics platform patent estate transferred to Roche while public shareholders received nothing. If the IP had value, why didn’t equity go with it? @lmdxtruthseeker keep finding more until they do what is right and pay those who invested. Biopharma released the liens a while ago. Pay the shareholders. #LMDX #Patents #IP #CorporateGovernance @CMAgovUK @FCA_UK @Roche @RocheDiagnostics @UKParliament @biztradegovuk

0 · Reply

lmdxxxxxxxxxx Dec. 29 at 4:27 AM

$FCN $LMDX $RHHBY Shareholders should ask themselves: Did my investment experience any of the following? 1. Material omission 2. Asymmetric disclosure 3. Information imbalance between regulators and investors 4. Misleading omission by silence 5. Selective disclosure 6. Failure to disclose going-concern alternatives 7. Failure to disclose internal forecasts 8. Failure to disclose asset-level valuation 9. Failure to disclose pipeline and IP value 10. Valuation suppression 11. Economic value stripping 12. Asset carve-out without fair valuation 13. Pre-pack process unfairness 14. Transaction-driven insolvency structuring 15. Inequitable treatment of shareholders 16. Unfair prejudice to minority shareholders 17. Transfer of upside without proportional risk sharing 18. Failure to maximize residual equity value 19. Conflicted transaction governance 20. Market integrity impairment If so you are not alone.

0 · Reply

Market Cap	5.26B
Revenue (ttm)	3.70B
Net Income (ttm)	280.09M
EPS (ttm)	N/A
PE Ratio	19.91
Forward PE	18.58
Profit Margin	7.57%
Debt to Equity Ratio	0.29

Volume	127,200
Avg Vol	327,898
Day's Range	N/A - N/A
Shares Out	30.88M
Stochastic %K	74%
Beta	0.09
Analysts	Sell
Price Target	$166.00